About the Company
at tcr2 therapeutics we have a bold vision – to cure cancer by using our immune system in a more natural way. we have developed a unique proprietary truc™ platform based on t cell receptor fusion constructs that have the advantage of employing the full signaling power inherent to a complete t cell receptor (tcr). our truc™ variants can reprogram the natural tcr complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. we have demonstrated activity against both hematological and solid tumor targets in preclinical models and we believe truc™-t cells will serve as the engine for novel therapies which we are quickly advancing towards the clinic. the company was founded in 2015 by dr. patrick baeuerle and backed with a $44.5m series a financing led by mpm capital and f2 ventures. we have since assembled a world class team of immunotherapy experts and entrepreneurs located in the heart of kendall square in cambridge, ma.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TCRR News
Tcr2 Therapeutics (NASDAQ: TCRR)
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the ...
TCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatment
Discover the groundbreaking patent by TCR2 Therapeutics Inc for T-cell receptor fusion proteins targeting tumor cell antigens. Revolutionizing disease treatment, including cancer, with engineered T ...
TCR2 Therapeutics GAAP EPS of -$1.56 misses by $0.74
TCR2 Therapeutics press release (NASDAQ:TCRR): Q4 GAAP EPS of -$1.56 misses by $0.74. TCR² ended the fourth quarter of 2022 with $149.2 million in cash, cash equivalents, and investments compared ...
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
This article Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying originally appeared on Benzinga.com.
FULC Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high ...
Cargo Therapeutics Inc CRGX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Todd Foley's Net Worth
Todd Foley has an estimated net worth of $598 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., iTeos Therapeutics, Inc., TriVascular ...
ATXS Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Outlook Therapeutics, Inc. (OTLK)
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of ...
Intellia Therapeutics Inc NTLA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Loading the latest forecasts...